Literature DB >> 25998118

The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research.

Kalyani Kansal1, David J Irwin2.   

Abstract

The gold standard for diagnosis of neurodegenerative diseases (ie, Alzheimer disease, frontotemporal dementia, Parkinson disease, dementia with Lewy bodies, amyotrophic lateral sclerosis) is neuropathologic examination at autopsy. As such, laboratory studies play a central role in antemortem diagnosis of these conditions and their differentiation from the neuroinflammatory, infectious, toxic, and other nondegenerative etiologies (eg, rapidly progressive dementias) that are encountered in neuropsychiatric practice. This article summarizes the use of cerebrospinal fluid (CSF) laboratory studies in the diagnostic evaluation of dementia syndromes and emerging CSF biomarkers specific for underlying neuropathology in neurodegenerative disease research.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Biomarkers; CSF; Dementia with Lewy bodies; Frontotemporal dementia; Neurodegenerative disease; Parkinson disease; Prion

Mesh:

Substances:

Year:  2015        PMID: 25998118      PMCID: PMC4443852          DOI: 10.1016/j.psc.2015.02.002

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  84 in total

1.  Diagnosis and treatment of cerebral vasculitis.

Authors:  Peter Berlit
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

2.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.

Authors:  Ryuichiro Atarashi; Katsuya Satoh; Kazunori Sano; Takayuki Fuse; Naohiro Yamaguchi; Daisuke Ishibashi; Takehiro Matsubara; Takehiro Nakagaki; Hitoki Yamanaka; Susumu Shirabe; Masahito Yamada; Hidehiro Mizusawa; Tetsuyuki Kitamoto; Genevieve Klug; Amelia McGlade; Steven J Collins; Noriyuki Nishida
Journal:  Nat Med       Date:  2011-01-30       Impact factor: 53.440

3.  Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Taim Muayqil; Gary Gronseth; Richard Camicioli
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

4.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  P Sanchez-Juan; A Green; A Ladogana; N Cuadrado-Corrales; R Sáanchez-Valle; E Mitrováa; K Stoeck; T Sklaviadis; J Kulczycki; K Hess; M Bodemer; D Slivarichová; A Saiz; M Calero; L Ingrosso; R Knight; A C J W Janssens; C M van Duijn; I Zerr
Journal:  Neurology       Date:  2006-08-22       Impact factor: 9.910

Review 5.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

6.  PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2.

Authors:  Franc Llorens; Belén Ansoleaga; Paula Garcia-Esparcia; Saima Zafar; Oriol Grau-Rivera; Irene López-González; Rosi Blanco; Margarita Carmona; Jordi Yagüe; Carlos Nos; José Antonio Del Río; Ellen Gelpí; Inga Zerr; Isidre Ferrer
Journal:  Prion       Date:  2013-09-18       Impact factor: 3.931

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Authors:  H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

9.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Authors:  Sara Hall; Annika Öhrfelt; Radu Constantinescu; Ulf Andreasson; Yulia Surova; Frederick Bostrom; Christer Nilsson; Widner Håkan; Hilde Decraemer; Katarina Någga; Lennart Minthon; Elisabet Londos; Eugeen Vanmechelen; Björn Holmberg; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  Arch Neurol       Date:  2012-11

10.  Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease.

Authors:  Mauricio Torres; Luis Cartier; José Manuel Matamala; Nancy Hernández; Ute Woehlbier; Claudio Hetz
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more
  5 in total

Review 1.  The Mental Status Examination in Patients With Suspected Dementia.

Authors:  Murray Grossman; David J Irwin
Journal:  Continuum (Minneap Minn)       Date:  2016-04

2.  Tract-Specific Relationships Between Cerebrospinal Fluid Biomarkers and Periventricular White Matter in Posthemorrhagic Hydrocephalus of Prematurity.

Authors:  Diego M Morales; Christopher D Smyser; Rowland H Han; Jeanette K Kenley; Joshua S Shimony; Tara A Smyser; Jennifer M Strahle; Terrie E Inder; David D Limbrick
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

3.  Plasma Neuron-Specific Enolase is not a reliable biomarker for staging Trypanosoma brucei rhodesiense sleeping sickness patients.

Authors:  Charles D Kato; Dorothy Twesigye; Vincent P Alibu; Ann Nanteza; Julius Nsubuga; Claire M Mugasa; Enock Matovu
Journal:  BMC Res Notes       Date:  2022-03-07

4.  Defining and predicting transdiagnostic categories of neurodegenerative disease.

Authors:  Eli J Cornblath; John L Robinson; David J Irwin; Edward B Lee; Virginia M-Y Lee; John Q Trojanowski; Danielle S Bassett
Journal:  Nat Biomed Eng       Date:  2020-08-03       Impact factor: 25.671

Review 5.  Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Authors:  Sonia Mayo; Julián Benito-León; Carmen Peña-Bautista; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.